menu search

ACET / Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit

Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit
REDWOOD CITY, Calif. & BOSTON--( BUSINESS WIRE )--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the virtual JMP Securities Hematology and Oncology Summit being held from December 6-7, 2022. Read More
Posted: Nov 30 2022, 16:00
Author Name: Business Wire
Views: 111652

ACET News  

Adicet Bio, Inc. (ACET) Reports Q2 Loss, Lags Revenue Estimates

By Zacks Investment Research
August 9, 2023

Adicet Bio, Inc. (ACET) Reports Q2 Loss, Lags Revenue Estimates

Adicet Bio, Inc. (ACET) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to los more_horizontal

Adicet Bio, Inc. (ACET) Reports Q1 Loss, Misses Revenue Estimates

By Zacks Investment Research
May 9, 2023

Adicet Bio, Inc. (ACET) Reports Q1 Loss, Misses Revenue Estimates

Adicet Bio, Inc. (ACET) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to ear more_horizontal

Adicet Bio: Searching For Upside In Cell Therapeutics

By Seeking Alpha
February 7, 2023

Adicet Bio: Searching For Upside In Cell Therapeutics

Biotechs developing CAR-T cell therapies have seen their valuations plummet in 2022 - making them an intriguing speculative buy opportunity in 2023. T more_horizontal

Are Medical Stocks Lagging Adicet Bio (ACET) This Year?

By Zacks Investment Research
January 25, 2023

Are Medical Stocks Lagging Adicet Bio (ACET) This Year?

Here is how Adicet Bio, Inc. (ACET) and AlloVir, Inc. (ALVR) have performed compared to their sector so far this year. more_horizontal

Down -53.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Adicet Bio, Inc. (ACET)

By Zacks Investment Research
December 30, 2022

Down -53.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Adicet Bio, Inc. (ACET)

Adicet Bio, Inc. (ACET) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined wit more_horizontal

Adicet Bio, Inc. (ACET) Loses 47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

By Zacks Investment Research
December 14, 2022

Adicet Bio, Inc. (ACET) Loses 47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Adicet Bio, Inc. (ACET) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement more_horizontal

Why The Adicet Bio (ACET) Stock Plummeted Over 35%

By Pulse2
December 12, 2022

Why The Adicet Bio (ACET) Stock Plummeted Over 35%

The stock price of Adicet Bio (ACET) plummeted over 35% intraday today. This is why. more_horizontal

Adicet Bio shares fall as it shares clinical data about its CAR-T treatment candidate

By Market Watch
December 12, 2022

Adicet Bio shares fall as it shares clinical data about its CAR-T treatment candidate

Adicet Bio's Inc. ACET, -13.13% stock tumbled about 38% in premarket trading on Monday after the company shared data from a Phase 1 clinical trial eva more_horizontal


Search within

Pages Search Results: